Patents Assigned to Aragon Pharmaceuticals, Inc.
  • Crystalline forms of an androgen receptor modulator
    Patent number: 12018008
    Abstract: Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.
    Type: Grant
    Filed: January 26, 2021
    Date of Patent: June 25, 2024
    Assignee: Aragon Pharmaceuticals, Inc.
    Inventors: Anna Dilhas, Mark R. Herbert, Ouathek Ouerfelli, Nicholas D. Smith
  • Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer
    Patent number: 11963952
    Abstract: Described herein are methods of treating metastatic castration-sensitive prostate cancer with anti-androgens, including but not limited to, 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide.
    Type: Grant
    Filed: February 13, 2023
    Date of Patent: April 23, 2024
    Assignee: Aragon Pharmaceuticals, Inc.
    Inventor: Margaret K. Yu
  • Anticancer compositions
    Patent number: 11911511
    Abstract: The present invention concerns pharmaceutical formulations of ARN-509, which can be administered to a mammal, in particular a human, suffering from an androgen receptor (AR)-related disease or condition, in particular cancer, more in particular prostate cancer, including but not limited to castration-resistant prostate cancer, metastatic castration resistant prostate cancer, chemotherapy-naive metastatic castration resistant prostate cancer, biochemically relapsed hormone sensitive prostate cancer, or high-risk, non-metastatic castration-resistant prostate cancer. In one aspect, these formulations comprise a solid dispersion of ARN-509, a poly(meth)acrylate copolymer and HPMCAS. In one aspect, the solid dispersion of ARN-509, a poly(meth)acrylate copolymer and HPMCAS is obtainable, in particular is obtained, by melt-extruding a mixture comprising ARN-509, a poly(meth)acrylate copolymer and HPMCAS and optionally subsequently milling said melt-extruded mixture.
    Type: Grant
    Filed: March 15, 2021
    Date of Patent: February 27, 2024
    Assignee: Aragon Pharmaceuticals, Inc.
    Inventor: Geert Verreck
  • Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer
    Patent number: 11903937
    Abstract: Described herein are methods of treating metastatic castration-sensitive prostate cancer with anti-androgens, including but not limited to, 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide.
    Type: Grant
    Filed: February 13, 2023
    Date of Patent: February 20, 2024
    Assignee: Aragon Pharmaceuticals, Inc.
    Inventor: Margaret K. Yu
  • Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment
    Patent number: 11723898
    Abstract: Described herein are methods of treating non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment with androgen receptor inhibitors, including but not limited to, 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: August 15, 2023
    Assignee: Aragon Pharmaceuticals, Inc.
    Inventors: Caly Chien, Peter Hellemans, Alex Yu
  • Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
    Patent number: 11491149
    Abstract: Described herein are methods of treating non-metastatic castrate-resistant prostate cancer using an approved drug product comprising apalutamide, enzalutamide or darolutamide. Also described here are drug products containing apalutamide enzalutamide or darolutamide, and methods of selling or offering for sale an anti-androgen drug product.
    Type: Grant
    Filed: May 28, 2020
    Date of Patent: November 8, 2022
    Assignee: Aragon Pharmaceuticals, Inc.
    Inventor: Arturo Molina
  • Anticancer compositions
    Patent number: 11224575
    Abstract: The present invention concerns pharmaceutical formulations of ARN-509, which can be administered to a mammal, in particular a human, suffering from an androgen receptor (AR)-related disease or condition, in particular cancer, more in particular prostate cancer, including but not limited to castration-resistant prostate cancer, metastatic castration resistant prostate cancer, chemotherapy-naive metastatic castration resistant prostate cancer, biochemically relapsed hormone sensitive prostate cancer, or high-risk, non-metastatic castration-resistant prostate cancer. In one aspect, these formulations comprise a solid dispersion of ARN-509, a poly(meth)acrylate copolymer and HPMCAS. In one aspect, the solid dispersion of ARN-509, a poly(meth)acrylate copolymer and HPMCAS is obtainable, in particular is obtained, by melt-extruding a mixture comprising ARN-509, a poly(meth)acrylate copolymer and HPMCAS and optionally subsequently milling said melt-extruded mixture.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: January 18, 2022
    Assignee: Aragon Pharmaceuticals, Inc.
    Inventor: Geert Verreck
  • Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
    Patent number: 11160796
    Abstract: Described herein are methods of treating non-metastatic castrate-resistant prostate cancer using an approved drug product comprising apalutamide, enzalutamide or darolutamide. Also described here are drug products containing apalutamide enzalutamide or darolutamide, and methods of selling or offering for sale an anti-androgen drug product.
    Type: Grant
    Filed: May 28, 2020
    Date of Patent: November 2, 2021
    Assignee: Aragon Pharmaceuticals, Inc.
    Inventor: Arturo Molina
  • Process for the preparation of a diarylthiohydantoin compound
    Patent number: 11040953
    Abstract: Disclosed are processes and intermediates for the preparation of compound (X), which is currently being investigated for the treatment of prostate cancer.
    Type: Grant
    Filed: July 27, 2020
    Date of Patent: June 22, 2021
    Assignee: Aragon Pharmaceuticals, Inc.
    Inventors: Cyril Ben Haim, Andras Horvath, Johan Erwin Edmond Weerts, Jennifer Albaneze-Walker
  • Anticancer compositions
    Patent number: 10966930
    Abstract: The present invention concerns pharmaceutical formulations of ARN-509, which can be administered to a mammal, in particular a human, suffering from an androgen receptor (AR)-related disease or condition, in particular cancer, more in particular prostate cancer, including but not limited to castration-resistant prostate cancer, metastatic castration resistant prostate cancer, chemotherapy-naive metastatic castration resistant prostate cancer, biochemically relapsed hormone sensitive prostate cancer, or high-risk, non-metastatic castration-resistant prostate cancer. In one aspect, these formulations comprise a solid dispersion of ARN-509, a poly(meth)acrylate copolymer and HPMCAS. In one aspect, the solid dispersion of ARN-509, a poly(meth)acrylate copolymer and HPMCAS is obtainable, in particular is obtained, by melt-extruding a mixture comprising ARN-509, a poly(meth)acrylate copolymer and HPMCAS and optionally subsequently milling said melt-extruded mixture.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: April 6, 2021
    Assignee: Aragon Pharmaceuticals, Inc.
    Inventor: Geert Verreck
  • Crystalline forms of an androgen receptor modulator
    Patent number: 10934271
    Abstract: Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.
    Type: Grant
    Filed: July 29, 2020
    Date of Patent: March 2, 2021
    Assignees: Aragon Pharmaceuticals, Inc., Sloan-Kettering Institute For Cancer Research
    Inventors: Anna Dihas, Mark R. Herbert, Ouathek Ouerfelli, Nicholas D. Smith
  • Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
    Patent number: 10849888
    Abstract: Described herein are methods of treating non-metastatic castrate-resistant prostate cancer with anti-androgens.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: December 1, 2020
    Assignee: Aragon Pharmaceuticals, Inc.
    Inventor: Isan Chen
  • Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
    Patent number: 10799488
    Abstract: Described herein are methods of treating non-metastatic castrate-resistant prostate cancer with anti-androgens.
    Type: Grant
    Filed: May 17, 2019
    Date of Patent: October 13, 2020
    Assignee: Aragon Pharmaceuticals, Inc.
    Inventor: Isan Chen
  • Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
    Patent number: 10799489
    Abstract: Described herein are methods of treating non-metastatic castrate-resistant prostate cancer with anti-androgens.
    Type: Grant
    Filed: May 20, 2019
    Date of Patent: October 13, 2020
    Assignee: Aragon Pharmaceuticals, Inc.
    Inventor: Isan Chen
  • Crystalline forms of an androgen receptor modulator
    Patent number: 10766875
    Abstract: Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: September 8, 2020
    Assignees: Aragon Pharmaceuticals, Inc., Sloan-Kettering Institute for Cancer Research
    Inventors: Anna Dihas, Mark R. Herbert, Ouathek Ouerfelli, Nicholas D. Smith
  • Processes for the preparation of a diarylthiohydantoin compound
    Patent number: 10723714
    Abstract: Disclosed are processes and intermediates for the preparation of compound (X), which is currently being investigated for the treatment of prostate cancer.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: July 28, 2020
    Assignee: Aragon Pharmaceuticals, Inc.
    Inventors: Cyril Ben Haim, Andras Horvath, Johan Erwin Edmond Weerts, Jennifer Albaneze-Walker
  • Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
    Patent number: 10702508
    Abstract: Described herein are methods of treating non-metastatic castrate-resistant prostate cancer using an approved drug product comprising apalutamide, enzalutamide or darolutamide. Also described here are drug products containing apalutamide enzalutamide or darolutamide, and methods of selling or offering for sale an anti-androgen drug product.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: July 7, 2020
    Assignee: Aragon Pharmaceuticals, Inc.
    Inventor: Arturo Molina
  • Crystalline forms of an androgen receptor modulator
    Patent number: 10556882
    Abstract: Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.
    Type: Grant
    Filed: July 10, 2019
    Date of Patent: February 11, 2020
    Assignees: Aragon Pharmaceuticals, Inc., Sloan-Kettering Institute For Cancer Research
    Inventors: Anna Dilhas, Mark R. Herbert, Ouathek Ouerfelli, Nicholas D. Smith
  • Crystalline forms of an androgen receptor modulator
    Patent number: 10526310
    Abstract: Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3,4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: January 7, 2020
    Assignees: Aragon Pharmaceuticals Inc., Sloan Kettering Institute for Cancer Research
    Inventors: Anna Dilhas, Mark R. Herbert, Ouathek Ouerfelli, Nicholas D. Smith
  • Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
    Patent number: RE49353
    Abstract: Described herein are methods of treating non-metastatic castrate-resistant prostate cancer with anti-androgens.
    Type: Grant
    Filed: August 20, 2020
    Date of Patent: January 3, 2023
    Assignee: Aragon Pharmaceuticals, Inc.
    Inventor: Isan Chen